# 美國最高法院支持藥廠Hikma Pharmaceuticals，裁定其仿製Amarin Pharma心血管藥物Vascepa的版本未侵犯Amarin持有的任何專利。

*biotech · news · 2026-06-06 · Devdiscourse*

## Key points

- 最高法院以9比0裁定Hikma的仿製Vascepa未侵犯Amarin的專利。
- 大法官Ketanji Brown Jackson撰寫一致決議，支持仿製藥製造商。
- 此判決推翻先前支持Amarin的下級法院裁決。
- 此判決可能降低仿製藥製造商面臨「精簡標籤」專利訴訟的風險。
- 該決定可能加速美國低價仿製藥的上市。

In a landmark decision, the U.S. Supreme Court has sided with drugmaker Hikma Pharmaceuticals, ruling that its generic version of Amarin Pharma's cardiovascular medication, Vascepa, does not infringe on any patents held by Amarin. This decisive 9-0 ruling was authored by liberal Justice Ketanji Brown Jackson. The court's ruling is seen as a significant victory for generic drugmakers, as it might reduce their vulnerability to patent lawsuits, which often involve so-called 'skinny labels'. Such cases have historically been a barrier to producing lower-cost generic drugs. This decision overturns a lower court ruling that had favored Amarin. By potentially lowering the threshold for similar lawsuits in the future, the Court's ruling could encourage the production and sale of cost-effective generic drugs, which may, in turn, help to lower the high drug prices faced by consumers across the United States. (With inputs from agencies.)

**Companies:** Hikma Pharmaceuticals
**Countries:** United States

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/health/3931133-us-supreme-court-boosts-generic-drugmakers-in-skinny-label-patent-case)

---

Canonical: https://newsio.io/zh-TW/n/d44903da-b4c0-438e-bb2e-13625f1af6ff/hikma-pharmaceuticalsamarin-pharmavascepaamarin
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works